Mankind Pharma net profit increases 29 percent to Rs 659 crore in Q2
New Delhi: Mankind Pharma has recorded a 29 per cent increase in consolidated net profit, reaching Rs 658.88 crore for the second quarter ended September 2024, driven by a recovery in volume. The company's net profit was Rs 511.18 crore in the July-September quarter last year, as stated in a regulatory filing.
Its revenue from operations increased 13.6 per cent to Rs 3,076.51 crore in the September quarter against Rs 2,708.10 crore a year ago.
The company had a "steady revenue growth of 13.6 per cent year-on-year with strong EBITDA margins of 27.7 per cent, driven by recovery in volume, continued outperformance in chronic segment and operating leverage," its Vice Chairman and Managing Director Rajeev Juneja said.
Its total expenses rose 9.8 per cent to Rs 2,339.19 crore in Q2 FY25, according to PTI.
The total income of Mankind Pharma, which includes other income, surged 15.09 per cent to Rs 3,185.94 crore in the September quarter.
Its domestic revenue increased 11 per cent to Rs 2,796 crore, while exports jumped 57 per cent to Rs 281 crore, Mankind Pharma said in its earnings statement.
Exports revenue was "driven by an increase in our base business supported by new launches in last 12-24 months", it said.
Read also: Mankind Pharma Completes Rs 13,768 Crore Acquisition of Bharat Serums
Founded in 1991 and commenced operation in 1995, Mankind Pharma is a pharmaceutical company engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.
Read also: Mankind Pharma CALDIKIND-P gets Delhi HC protection from lookalike CALIKA-P
